Exponent IncEXPO

Exponent Inc is a science-and-engineering consultancy dressed in a PowerPoint tuxedo, promising clients the data-driven certainty that only Ph.D.s can deliver. From product recalls in baby cribs to carcinogenic effluent testing in next-gen car plants, the firm’s multidisciplinary teams bill themselves as the arbiters of safety, performance and regulatory compliance across industries from consumer electronics to utilities. The marketing site shows data scientists in soft focus, crib mattresses in sharp focus, and industrial plants in heroic focus-all suggesting a business that converts uncertainty into neat reports and predictable fees. (source: Exponent product rails: Product Safety & Recall, Technology, Data & Innovation, Industrial Operations & Technology, Consumer Products).

The problem is that the first-quarter filing for 2026 shows a company that knows how to recognise revenue but not necessarily how to collect it: revenues reported at $166.3 million for the quarter, while operating cash flow dribbled out at minus $975,000. The balance sheet still looks sturdy-$338.3 million in shareholders’ equity and $118.6 million in cash-but the cash-cycle lesson is simple: when you outsource the heavy lifting to subcontractors and act as a fee-taking agent, the cash can take longer to arrive than the PowerPoint slides. (source: SEC EDGAR 10-Q for the quarter ended 2026-04-03, https://www.sec.gov/Archives/edgar/data/851520/000119312526214572/expo-20260403.htm).

The filing quietly reveals another quirk: Exponent recognised $7.4 million of revenues that were tucked inside deferred revenue at the start of the year, a line that acts like a financial airbag for quarterly optics. Meanwhile, subcontractor fees not counted as revenue clocked in at $6.8 million this quarter, up from $3.5 million a year ago, which neatly illustrates the agency model’s double edge: you get the fee without the balance-sheet risk, but the client’s cash doesn’t always follow the same paper trail. Diluted EPS came in at $0.59 on 50.1 million shares, and the company dished out $2.5 million on capex while the operating cash flow statement yawned. (source: SEC EDGAR 10-Q for the quarter ended 2026-04-03, https://www.sec.gov/Archives/edgar/data/851520/000119312526214572/expo-20260403.htm; Weighted Average Shares Outstanding, Diluted, and EPS per 10-Q).

If the company’s marketing promises precision, the cash-flow line delivers a reminder that precision costs money. The footnotes also flag that the firm acts as an agent for subcontractor services, booking fees while the underlying cash may sit with third parties. That’s not fraudulent-it’s standard agency accounting-but it does mean the cash-conversion cycle can lag the revenue recognition, which the market tends to notice only when the deferred revenue is finally unwound and the cash is still in transit. The SEC filings this month show a company that can bill like a tech disruptor but bank like a traditional consultancy: plenty of deferred promises, fewer immediate deposits. (source: SEC EDGAR 10-Q for the quarter ended 2026-04-03, https://www.sec.gov/Archives/edgar/data/851520/000119312526214572/expo-20260403.htm; SEC EDGAR 10-K for the year ended 2026-01-02, https://www.sec.gov/Archives/edgar/data/851520/000085152026000090/xslF345X06/edgardoc.xml).

The chart rail is light on this one: the evidence set does not supply a trading-view route or price history that we can cite without inventing levels. The company is listed on NASDAQ under the symbol EXPO, but the file contains no daily price data or volume series to anchor a technical read. For context, the latest 10-Q shows total assets of $687.4 million against liabilities of $349.0 million, so the balance sheet is structurally solvent even if the cash-flow engine is occasionally wheezy. If you want to see the price action, you’ll need to consult a live market data terminal, not this filing. (source: SEC EDGAR 10-Q for the quarter ended 2026-04-03, https://www.sec.gov/Archives/edgar/data/851520/000119312526214572/expo-20260403.htm).

The recent SEC activity is unusually busy for a consultancy: multiple 8-Ks and Forms 4 and 144 filed in June and July, suggesting insider selling and equity-placement activity that the market reads as dilution risk rather than confidence. The company’s product rails-product safety, tech data, industrial ops-remain credible and well-documented, but the financial cadence doesn’t yet match the marketing tempo. Until the operating cash flow turns reliably positive, the story remains a tale of deferred ambition rather than delivered value. (source: SEC EDGAR filing index and submissions JSON, https://www.sec.gov/edgar/browse/?CIK=851520; https://data.sec.gov/submissions/CIK0000851520.json).